C4 therapeutics announces key 2021 milestones to support progress toward goal of four clinical-stage programs by year-end 2022

– investigational new drug (ind) application for lead candidate cft7455, a monodac™ targeting ikzf1/3 for the treatment of hematologic malignancies, under fda review; initiation of phase 1/2 trial expected in 1h 2021 –

CCCC Ratings Summary

CCCC Quant Ranking